Venous thromboembolism Deep vein thrombosis Pulmonary embolism Direct oral anticoagulants Systematic literature review Network meta-analysis A B S T R A C T The aim of this study was to systematically review published network meta-analyses (NMAs) that compare venous thromboembolism (VTE) treatments.
Introduction
Venous thromboembolism (VTE), a condition that includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with significant morbidity and mortality. Although warfarin has been the standard oral anticoagulant VTE treatment for several years, direct oral anticoagulants (DOACs), either preferred to vitamin K antagonists (VKAs) or as an alternative to VKAs, have been currently recommended by several clinical guidelines because of their superior safety profile with respect to bleeding [1, 2] . Reduced rates of fatal bleeding, major bleeding, and clinically relevant non-major bleeding (CRNMB) with DOACs compared to VKAs have been reported in a prior meta-analysis [3] . In managing patients with VTE, healthcare providers face the challenge of balancing the benefits of DOACs, such as their efficacy and safety in reducing risk of recurrent VTE and other thromboembolic phenomena, and the risk of side effects, mainly bleeding [4, 5] . DOACs have fewer treatment management complexities and are more convenient for patients and clinicians, as they do not require the regular monitoring of international normalization ratio (INR) or have the drug interactions associated with use of VKAs [6] .
The comparative efficacy and safety of DOACs versus VKAs or placebo for the management of VTE in the acute and extended treatment settings have been demonstrated in phase II and III randomized controlled trials. Key trials in the treatment of acute VTE by DOACs include: apixaban (AMPLIFY, BOTICELLI -DVT), [7, 8] dabigatran (RE−COVER, RE−COVER II) [9, 10] , edoxaban (HOKUSAI-VTE) [11] , and rivaroxaban (EINSTEIN DVT, EINSTEIN DVT-dose ranging, EIN-STEN PE, ODiXa-DVT) [12] [13] [14] . The four DOAC trials in the extended treatment settings include three of the four comparators as the acute setting -apixaban (AMPLIFY-EXT) [15] , dabigatran (RE-SONATE, RE-MEDY) [16] , and rivaroxaban (EINSTEIN-EXT) [13, 17] .
Major bleeding is not uncommon in the treatment of acute VTE where the incidence of bleeding is highest and anticoagulant interruption may have significant clinical consequences [18] . However in the extended setting, the burden of bleeding continues but major bleeding occurs at a significantly lower incidence rate and therefore fewer events are seen. Hence in the extended setting clinically relevant bleeding (CRB), the composite of major and CRNM bleeding becomes the outcome of interest as it includes major bleeding and clinically relevant non-major bleeding. These two components of CRB are of importance to clinicians and patients.
Better understanding of the best treatment to prevent or reduce the risk of bleeding events during treatment with DOACs for VTE may enable health professionals when the decision on intensity and VTE treatment is reached. Due to the lack of direct comparisons of DOACs in patients with VTE in randomized controlled trials (RCTs), several indirect comparisons such as network meta-analyses (NMAs) have been undertaken to estimate the relative safety and efficacy among DOACs. In order to bring the evidence together from the different NMAs and summarize the results collectively, we undertook a systematic literature review (SLR) of published NMAs to examine the methodological approach and outcomes of the NMAs and to help answer the important clinical questions concerning the efficacy and safety of DOACs in the treatment of VTE.
Methods
The systematic literature review (SLR) was conducted and reported according to the recommendations of the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) Statement [19, 20] . MEDLINE, Embase, and the Cochrane Database of Systematic Reviews databases were searched to identify English-language NMAs published between January 1, 2010 and September 29, 2017. The full search strategies are reported in the S1 Appendix (S1Table 2).
Studies that met the following predefined eligibility criteria were systematically identified for inclusion in the review: NMAs including RCTs evaluating multiple comparisons of DOACs, low-molecular weight heparin (LMWH), unfractionated heparin (UFH), and VKAs as VTE therapies in the acute or extended treatment settings and reporting at least one outcome of interest. Outcomes of interest included recurrent/ symptomatic VTE (DVT, PE, or both), mortality, and bleeding (major bleeding (which includes fatal bleeding), clinically relevant non-major bleeding (CRNMB), the composite of these, clinically relevant bleeding (CRB) or any other bleeding types). NMAs were required to have included ≥ 90% patients with VTE (DVT or PE) or report outcomes data separately for VTE subjects. NMAs of observational studies, NMAs of RCTs evaluating DOACs for primary prevention, and meta-analyses that pooled data from RCTs evaluating similar comparisons were excluded.
Titles and abstracts of citations identified from the searches were evaluated using the above-mentioned pre-specified criteria. Citations at the title and abstract level were excluded if they clearly did not meet inclusion/exclusion criteria. Full texts were obtained for the citations that were included after this first screening stage, and these were evaluated again based on the inclusion/exclusion criteria. Screening was conducted by two investigators who were trained at the objectives of the SLR, and disagreements were resolved by a third senior investigator. For each NMA included in the review, data on study characteristics, methodology, and outcomes of interest were extracted by one investigator and validated for accuracy by a second investigator.
The quality of evidence (effect estimates) from the identified NMAs was rated for each comparison and outcome based on the guidance by the Grading of Recommendations and Evaluation (GRADE) Working Group [21] . Direct, indirect and NMA effect estimates were presented and its quality were rated using the recommended GRADE domains: risk of bias, inconsistency, indirectness, incoherence, and imprecision [21] . Of note, indirect evidence was examined for the RCTs in the first order loop of the evidence network via the common comparator of VKA or placebo (network comparisons involving only a single additional intervention) as suggested by this GRADE guidance.
Evidence from the identified NMAs comparing DOACs versus other DOACs or non-DOACs was synthesized. Results are presented for all other DOACs and non-DOACs compared to apixaban as only apixaban had demonstrated reductions in major bleeding and clinically relevant non-major bleeding versus VKA [7] . Estimates of treatment effects and their corresponding credible intervals were compiled and presented in forest plots per each outcome of interest, namely bleeding (safety) and recurrent VTE (DVT and or PE) (efficacy). Results for other outcomes are summarized in figures and presented in S1 Appendix.
Results

SLR results
The search identified 294 unique records and these were reviewed at the title/abstract level. We included 22 records for review at the fulltext level, and identified nine NMAs for inclusion that reported data across 68 primary trials for comparisons among apixaban, other DOACs, LMWH, and UFH [22] [23] [24] [25] [26] [27] [28] [29] [30] . A PRISMA diagram detailing the flow of NMAs during the screening process is shown in Fig. 1 .
A summary of the characteristics of the included NMAs are presented in Table 1 . Of the nine included NMAs, three of them evaluated outcomes related to the acute treatment setting [24, 26, 27] , five evaluated outcomes for the extended-treatment setting [22, 23, 25, 28, 29] , and one NMA evaluated outcomes in both settings [30] . Across all nine NMAs, the population examined was patients with symptomatic VTE (DVT or PE). Across the four NMAs evaluating DOACs in the acute treatment setting, all NMAs included the AMPLIFY, EINSTEIN-DVT, EINSTEIN-PE, RECOVER I and RECOVER II RCTs. Three of the four NMAs also included the HOKUSAI-VTE trial. One NMA in the acute setting had broader inclusion criteria of anticoagulant comparisons thus included a larger evidence network of 45 trials [23] . Similarly, the trials overlapped across the NMAs in the extended treatment setting. The specific trials included in each NMA are summarized in Table 2 . The AMPLIFY-EXT, EINSTEIN-EXT and RESONATE trials were included in all six NMAs evaluating DOACs in the extended treatment setting.
Both licensed and unlicensed treatments were evaluated by the included NMAs (Table 1 ). The presentation of NMA results focuses on the licensed doses whereas the results for the unlicensed doses can be found in the S1 Appendix.
More than half the NMAs (n = 5; 56%) used a Bayesian methodology [23] [24] [25] 28, 30] . Other less commonly used approaches included the Bucher method (n = 1) [27] and frequentist method (n = 1) [29] . The approach used was unclear in two NMAs [22, 26] . Three NMAs used a fixed-effects model [25, 26, 30] , two NMAs used a random-effects model [28, 29] and two NMAs used both the fixed-and random-effects models [23, 24] . Two NMAs did not specify the type of statistical model that was used (Table 1) [22, 27] .
GRADE quality assessment
A summary of the GRADE assessment with rationale for down-rating of the evidence is presented in S1Tables 3-5. The GRADE assessment was conducted for the direct estimates from RCT data included in the NMAs (when available), the indirect evidence and the NMA evidence for the outcomes and comparisons of interest. A summary of the GRADE A.T. Cohen, et al. Pharmacological Research 143 (2019) [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] assessment results for apixaban vs. dabigatran, edoxaban and rivaroxaban is summarized in Table 3 and outlined in Section 3.4.1 and Section 3.4.2.
Acute treatment of VTE
In the RCTs evaluating DOACs in the acute treatment of VTE, across bleeding, recurrent VTE and all-cause mortality outcomes, the direct evidence ranged from high quality to very low quality, but all of the very low quality direct evidence was from trials evaluating unlicensed doses. When the direct evidence was down rated, the main reasons were due to risk of bias mostly due to lack of blinding of participants/personnel and for imprecision of effect estimates.
The outcomes and comparisons with NMA estimates of the highest rated quality were apixaban 10 mg then 5 mg BID vs. edoxaban 60 mg or 30 mg OD and apixaban 10 mg then 5 mg BID vs. dabigatran 150 mg BID. These comparisons for major bleeding and CRB were rated of moderate or high quality (Table 3) . For recurrent VTE/DVT/PE and allcause mortality, the quality of the NMA estimates ranged from moderate to very low across DOAC comparisons, with the comparison of rivaroxaban 15 mg BID then 20 mg OD rated as very low quality across all outcomes (Table 3) .
Extended treatment of VTE
In the RCTs evaluating DOACs in the extended treatment setting, the quality of the direct evidence ranges from moderate to low quality for major bleeding, from high to moderate for recurrent VTE, from moderate to low for recurrent DVT, from high to low for recurrent PE, and from high to very low for all-cause mortality.
In the evidence in the extended treatment setting, the only comparison and outcome with a moderate quality rating was apixaban 2.5 mg BID vs. dabigatran 150 mg BID for risk of CRB. The comparison of apixaban 2.5 mg and 5 mg BID vs. dabigatran 150 mg BID for risk of recurrent VTE ranged from moderate to very low. For all other comparisons and outcomes in the extended treatment setting, the quality ranged from low to very low (Table 3 ).
Safety outcomes
Major bleeding
A summary of the evidence on major bleeding for acute VTE treatment and extended treatment settings are provided in Figs. 2 and 3, respectively. Comparative evidence on major bleeding between apixaban 10 mg then 5 mg twice per day (BID) and other anticoagulants for acute VTE treatment were reported across four NMAs [24, 26, 27, 30] (Fig. 2) . Overall, the risk of major bleeding was significantly lower with apixaban 10 mg BID then 5 mg BID compared with LMWH-dabigatran 150 mg BID, LMWH-edoxaban 60 mg or 30 mg OD, and fondaparinux-VKA combination in the treatment of acute VTE (range of effect estimates: 0.30-0.43; Fig. 2 ). The difference in risk of major bleeding was not significant between apixaban 10 mg then 5 mg BID compared to rivaroxaban 15 mg BID then 20 mg OD for treatment of acute VTE (Fig. 2) . Overall, the risk of major bleeding was significantly lower with apixaban 5 mg and 2.5 mg compared with rivaroxaban 15 mg BID then 20 mg OD in the extended treatment setting (range of effect estimates: 0.02-0.03; Fig. 3 ).
None of the NMAs evaluated the risk of CRNMB in the acute treatment of VTE for the comparisons of interest. Evidence on CRNMB in the extended treatment setting was reported by three NMAs [22, 25, 28] (S1Fig. 4). The risk of CRNMB was significantly lower with apixaban 2.5 mg BID compared with rivaroxaban 20 mg OD [22, 25] ; one study reported a difference compared to dabigatran 150 mg BID [22] , while the other study found no difference [25] (S1Fig. 4). In contrast, the risk of CRNMB with apixaban 5 mg BID compared to rivaroxaban 20 mg OD varied between NMAs-one reported a significant difference in favor of apixaban [22] , but another NMA found no difference [28] . The results for apixaban 5 mg BID compared to dabigatran 150 mg BID were also varied between NMAs. One study reported a significantly lower risk with apixaban 5 mg BID compared with dabigatran 150 mg BID, but two NMAs found no differences [22, 28] (S1Fig. 4).
Results of the analyses of CRB (the composite outcome of major bleeding and CRNMB) were reported by two NMAs in the treatment of acute VTE [26, 30] and by three NMAs in the extended treatment setting [25, 29, 30] . In the treatment of acute VTE, apixaban 10 mg then 5 mg BID was associated with significant reduction in risk of CRB compared with dabigatran 150 mg BID, edoxaban 60 mg or 30 mg OD, and rivaroxaban 15 mg BID then 20 mg OD (range of effect estimates: 0.47-0.72; Fig. 4 ). In the extended treatment setting, the risk of CRB was significantly lower with apixaban at both 2.5 mg BID and 5 mg BID doses than rivaroxaban 20 mg OD (range of effect estimates: 0.01-0.24; One NMA showed a significant risk reduction with apixaban 5 mg BID compared with dabigatran 150 mg BID, while a second NMA showed no difference.
Evidence on the risk of intracranial bleeding in the acute treatment setting was reported in only one study and indicated there were no differences between apixaban and comparators (dabigatran 150 mg BID, edoxaban 60 mg or 30 mg OD, and rivaroxaban 15 mg BID then 20 mg OD) in the acute treatment setting [26] (S1Fig. 5). Data for intracranial bleeding were not reported in the extended treatment setting. None of the NMAs reported comparative evidence on gastrointestinal bleeding.
Efficacy outcomes
Recurrent VTE/DVT/PE
Comparative indirect evidence on the risk of recurrent VTE/DVT/PE between apixaban and other DOACs and non-DOACs in the acute and extended treatment settings were reported in four NMAs [24, 26, 27, 30] and five NMAs [22, 23, 25, 29, 30] , respectively. There were no significant differences in the risk of recurrent VTE (DVT or PE) between apixaban and the evaluated comparators in either treatment setting (the treatment of acute VTE or the extended treatment) (Figs. 6 and 7) . Additionally, there were no differences in risk of recurrent DVT or recurrent PE in either treatment setting (data not shown).
All-cause mortality
Comparative indirect evidence on the risk of all-cause mortality between apixaban and other DOACs and non-DOACs in the acute [26, 27, 30] and extended [22, 25, 30] treatment settings were reported in three NMAs each. There were no significant differences in the risk of all-cause mortality between apixaban and the evaluated comparators in both treatment settings (S1Fig. 6 and S1Fig. 7). Abbreviations: AE = adverse event; BID = twice per day; CRB = clinically relevant bleeding; CRNMB = clinically relevant non-major bleeding; DOAC = direct oral anticoagulant; DVT = deep venous thrombosis; ITC = indirect treatment comparison; LMWH = low-molecular weight heparin; NMA = network meta-analysis; OD = once daily; PE = pulmonary embolism; PICOS = patients, intervention, comparator, outcomes, study design; QW = once per week; RCT = randomized controlled trial; SLR = systematic literature review; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = venous thromboembolism. Abbreviations: BID = twice per day; CRB = clinically relevant bleeding; CRNMB = clinically relevant non-major bleeding; DVT = deep venous thrombosis; OD = once daily; PE = pulmonary embolism; VTE = venous thromboembolism.
Discussion
Across nine NMAs evaluating the safety and efficacy of DOACs for the treatment of VTE, the indirect evidence consistently points to a significant reduction in risk of major bleeding and clinically relevant bleeding with apixaban compared to other DOACs. Evidence of moderate to high quality confirmed consistently that treatment with apixaban significantly reduced the risk of major bleeding compared to dabigatran, edoxaban, and also fondaparinux-VKA combination, in all published indirect comparisons. Clinically relevant bleeding was also significantly reduced with apixaban compared with dabigatran, edoxaban, and rivaroxaban. Results relating to major bleeding and clinically relevant bleeding events were consistent across the NMAs, independently of any differences in the design and execution of these analyses. There were no differences in efficacy outcomes between the DOACs, but uncertainty for some of these results was high, given the wide credible intervals, especially those for all-cause mortality. However, for some comparisons, the NMAs reported inconsistent results. This is likely to be due to differences in the number of RCTs contributing to the evidence network for each NMA, with larger networks having been included in more recent NMAs compared to the earliest example. Additionally, some NMAs had different inclusion/ exclusion criteria and different methodological approaches (random vs. fixed effects) although not enough information were available in the NMA publications to further explore the impact of such differences in the observed results. There were generally no significant differences between apixaban and other anticoagulants for the following outcomes: intracranial bleeding, recurrent/symptomatic VTE/DVT/PE, non-fatal DVT, non-fatal PE, or all-cause mortality. This SLR of NMAs and indirect treatment comparisons of DOACs provides a new insight into the relative impact of apixaban compared to other anticoagulants for the most clinically relevant outcomes in patients with VTE. Additionally, this SLR considered the quality of the evidence contributed to each of the quantitative results by applying a well-established NMA quality tool which further reinforces the validity of its conclusions.
Providing therapy with a good safety profile is especially important in patients with VTE who require extended or indefinite anticoagulation as the majority of the burden of bleeding occurs in this setting.
Bleeding incidence is highest in the acute and standard treatment phases and bleeding may lead to the interruption or even the early discontinuation of anticoagulation in the phase where this therapy is most critical. In the first three months of anticoagulant therapy for VTE, bleeding and VTE recurrences have similar case fatality but after the first three months of treatment, the case fatality rates for bleeding are three times higher than those of recurrences [1, [31] [32] [33] . Despite the extensive data on the effectiveness of appropriately managed anticoagulants, fear of bleeding events leads to premature discontinuation resulting in a loss of benefit [34] .
In the present study, for patients requiring extended treatment, the collective body of indirect evidence from the NMAs points to a reduced risk of major bleeding with apixaban compared to rivaroxaban. Significant reduction in the risk of clinically relevant bleeding was seen with apixaban 2.5 mg BID compared to rivaroxaban and dabigatran and apixaban 5 mg BID compared with rivaroxaban across indirect comparisons. Results of this review provide insight into the relative impact of DOACs and other anticoagulants in the overall VTE population. Results of this review align with previous evidence of a net clinical benefit of apixaban compared with other DOACs [35] . Similar benefits in the risk of major bleeding have been reported with apixaban compared to VKAs and DOACs in non-valvular atrial fibrillation and in the primary prevention of VTE [36] [37] [38] [39] . A recent observational study in non-valvular atrial fibrillation examined the safety and efficacy of different DOACs in four large, US commercial claims databases, and showed that apixaban was associated with a lower risk of stroke/systemic embolism and major bleeding compared to dabigatran and Abbreviations: BID = twice per day; CI = confidence interval; FE = fixed effect; HR = hazard ratio; LMWH = low-molecular weight heparin; NMA = network metaanalysis; OD = once daily; OR = odds ratio; RE = random effect; RR = relative risk; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = venous thromboembolism rivaroxaban [40] .
Evidence on the comparative efficacy and safety of DOACs and other anticoagulants on the components of major bleeding, such as gastrointestinal bleeding, is unclear. Such data were not reported in any of the NMAs included in this review although collected by some of the included RCTs.
The present study evaluated the quality of estimates from the NMAs using the GRADE framework. The evidence for major bleeding and clinically relevant bleeding was of the highest quality thus we are the most confident in results of NMAs comparing DOACs with respect to these outcomes. The risk of major bleeding was significantly reduced with apixaban compared to dabigatran, edoxaban, and also fondaparinux-VKA combination in all published indirect comparisons. The risk of clinically relevant bleeding was also significantly reduced with apixaban compared with dabigatran, edoxaban, and rivaroxaban. The evidence for non-major clinically relevant bleeding, recurrent VTE/ Abbreviations: BID = twice per day; CI = confidence interval; FE = fixed effect; HR = hazard ratio; LMWH = low-molecular weight heparin; NMA = network metaanalysis; OD = once daily; OR = odds ratio; RE = random effect; RR = relative risk; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = venous thromboembolism DVT/PE and all-cause mortality were rated of low to very low quality and should be interpreted cautiously. The most common reason for down-rating the quality of this evidence was for imprecision, which was likely driven by a low number of trials available for each DOAC comparison and low frequency of occurrence of these outcomes.
Limitations and strengths
To best of our knowledge, this is the first SLR of NMAs in acute and extended treatment setting for VTE. This SLR adds to the gains seen by prospectively planned living NMA, which can facilitate timely treatment recommendations and avoid unnecessary research waste by providing strong evidence for the effectiveness of different treatments in a disease area [41] . Although this SLR aimed to identify the most robust direct and indirect evidence from NMAs comparing apixaban versus other DOACs or non-DOACs, there were some limitations that could restrict the applicability of its findings. Firstly, the search was restricted to English peer reviewed publications so relevant NMA publications in other languages or published in non-indexed sources (such as HTA websites) may have been missed. This SLR did not conduct a separate search of RCTs comparing apixaban versus other treatment for the treatment of VTE in either acute or extended setting, so there may be a possibility the retrieved NMAs have missed relevant publications in this area. Another important consideration when evaluating the results of this SLR of NMAs is that there was significant overlap in the RCTs included across the NMAs and each SLR was searched at a different date. Therefore, older NMAs will not have as much evidence contributing to the network as more recently published NMAs. This may have resulted in different findings for the same outcome and same comparisons published at different dates. Furthermore, the lack of information available regarding the primary RCTs included in the NMAs has restricted in some instances the presentation and quality assessment of effect estimates. Also, it is difficult to make any assertions on the optimal anticoagulants in specific subpopulations, such as patients with reduced renal function, cancer or other comorbidities because such evidence was lacking in the included NMAs. A possible reason for this could be the lack of the reporting of subgroup data in primary trial publications. It is likely that some of these data are reported in secondary publications that were not identified by NMAs.
Furthermore, NMA as a statistical technique inherits all the methodological challenges present in a standard meta-analysis (assessment of bias, heterogeneity, precision, and reliability of estimates) but with increased complexity due to the number of comparisons involved. Strong assumptions required for NMAs, such as homogeneity (equivalence of treatment effects across trials within each pairwise comparison), transitivity (the validity of making indirect comparisons), and consistency (the equivalence of direct and indirect evidence) must be met [42] [43] [44] . In our example, NMA data were the only way to estimate comparative treatment effects between DOACs for VTE, given that there were no RCTs with direct comparisons among these treatments of interest. This review was restricted to the information at the NMA level, including inclusion and exclusion criteria and outcome definitions. Based on the authors' clinical expertise, the trials had similar inclusion/ exclusion criteria of adult patients with VTE (PE and/or DVT) who were not taking medication or had conditions that would interfere with DOAC treatment. Across the trials, most outcomes, including stroke and major bleeding, had similar definitions, but there is typically more heterogeneity in how clinically relevant non-major bleeding is defined and interpreted. For example, some studies define clinically relevant non-major bleeding as overt bleeding not meeting the criteria for major Fig. 7 . Recurrent VTE-Extended Treatment. Abbreviations: BID = twice per day; CI = confidence interval; FE = fixed effect; NMA = network meta-analysis; QW = once per week; OD = once daily; OR = odds ratio; RE = random effect; RR = relative risk; VTE = venous thromboembolism *Results for extended follow-up period bleeding but associated with medical intervention, contact with a physician, interruption of the study drug, or discomfort or impairment in carrying out activities of daily life. Other studies classify bleeding into major and anything that is not major, which is classified as minor or clinically relevant non-major bleeding. Studies can also define nonmajor bleeding by their own criteria, such as presence of skin hematoma, nose bleed, rectal bleed, bleeding leading to hospitalization, or anything deemed clinically relevant by the investigator. Furthermore, we assessed the quality of the evidence (direct, indirect) fitted in the NMAs and the strength of the NMA results by implementing the GRADE assessment, a well-recognized, international tool of assessing the quality of NMAs. Further research is required to confirm clinical similarities across the trials included across NMAs.
Conclusion
In our SLR of NMAs in trials of patients with VTE, most of the evidence points to a significant reduction in risk of major bleeding and clinically relevant bleeding with apixaban (10 mg then 5 mg BID dose) compared to dabigatran, edoxaban, and the fondaparinux-VKA combination in the acute VTE treatment setting. In the extended treatment setting, there was a reduction of risk of major bleeding with apixaban (2.5 mg or 5 mg BID doses) compared to dabigatran and rivaroxaban. In the absence of head-to-head trials, which are needed to fully understand comparative efficacy and safety of DOACs and other anticoagulants used in the management of VTE, well-conducted NMAs provide the best evidence. SE Berger and D Milenković are employed by Evidera Inc., which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payments or honoraria directly from these organizations for services rendered.
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